Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study

Read full text Summarise with VIRAT
Authors: Judith Trotman, Krimo K. Bouabdallah, Fontanet Delices Bijou, D. Šálek, A.C. de Oliveira, Y. Song, Edwin C. Kingsley, Christopher R. Flowers, S. Liao, S. Huang, Nirav Niranjan Shah, L. Dumartin
+1 more PL Zinzani
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: The phase II ROSEWOOD study (NCT03332017) compared zanubrutinib plus obinutuzumab (ZO) with obinutuzumab monotherapy (O) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who had received two or more prior lines of systemic therapy. Median progression-free survival (PFS) was longer with ZO versus O [28.0 versus 10.4 months; hazard ratio 0.50, 95% confidence interval (CI) 0.33-0.75]. MATERIALS AND METHODS: In this post hoc analysis, an intra-patient comparative analysis was carried out using the growth modulation index (GMI) to analyze the efficacy of ZO versus the last prior treatment received by patients in the ROSEWOOD study. A GMI of ≥1.33 was used as a threshold for significant clinical activity. RESULTS: In the overall population, median GMI was 2.7 (95% CI 1.6-4.9) in the ZO arm and 0.9 (95% CI 0.5-1.7) in the O arm. Analysis in subgroups of clinical interest in the ZO arm showed that PFS was longer with ZO than with the last prior treatment, and median GMI was ≥1.33 in all subgroups tested. Overall, PFS had improved (GMI ≥1.33) in >60% of patients with R/R FL who received ZO versus their last prior treatment. CONCLUSIONS: This GMI analysis further supports the benefit of ZO as a novel therapeutic option for patients with R/R FL.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
ESMO Open
Volume
11
Issue
4
Pages
106942–106942
Publication date
31 March 2026
Language
EN